In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biolinerx (NASDAQ: BLRX), with a price target of $4. The company’s shares closed on Friday at $1.01.
Pantginis wrote:
“Blast mobilization correlates with increased survival. and investigators provided an incremental survival update from the Phase 2a BL-8040 study in relapsed/refractory AML patients. Importantly, and new to this study, is the identification of a biomarker, which appears to directly correlate with BL-8040’s impact on survival. Recall that median overall survival in this dose ranging study (0.5-2.0 mg/kg) was 9.2 months, which compares favorably to the historical expected survival of HiDAC alone of 6.1 months. Further, median overall survival at the 1.5 mg/kg dose was 10.7 months, with 1- and 2-year survival rates of 38.1% and 23.8%, respectively.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -8.7% and a 37.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Checkpoint Therapeutics Inc.
Currently, the analyst consensus on Biolinerx is Strong Buy and the average price target is $3, representing a 197.0% upside.
In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $3 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.34 and a one-year low of $0.78. Currently, Biolinerx has an average volume of 344.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi’in, Israel.
